|
AU2002362443B2
(en)
*
|
2001-10-01 |
2008-05-15 |
University Of Virginia Patent Foundation |
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
WO2007120972A2
(en)
*
|
2006-02-10 |
2007-10-25 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
|
KR20150038395A
(ko)
|
2006-04-04 |
2015-04-08 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
HRP20120494T1
(hr)
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Derivati purina za uporabu kao agonista adenozin a2a receptora
|
|
US8188063B2
(en)
*
|
2006-06-19 |
2012-05-29 |
University Of Virginia Patent Foundation |
Use of adenosine A2A modulators to treat spinal cord injury
|
|
US7906518B2
(en)
*
|
2006-06-27 |
2011-03-15 |
Cbt Development Limited |
Therapeutic compounds
|
|
EP1889846A1
(en)
*
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
US7985754B2
(en)
*
|
2006-07-17 |
2011-07-26 |
Trovis Pharmaceuticals, Llc |
Selective antagonists of A2A adenosine receptors
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
JP2010508835A
(ja)
*
|
2006-11-10 |
2010-03-25 |
ノバルティス アーゲー |
シクロペンテンジオールモノアセテート誘導体
|
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
BRPI0906473A8
(pt)
|
2008-01-04 |
2016-02-10 |
Intellikine Inc |
Certas entidades químicas, composições e métodos
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
MX2011000216A
(es)
|
2008-07-08 |
2011-03-29 |
Intellikine Inc |
Inhibidores de cinasa y metodos para su uso.
|
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
AU2009305669A1
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
US20130123208A1
(en)
*
|
2010-05-12 |
2013-05-16 |
The Regents of the University of Colorado, a body corporation |
Method of treating multiple sclerosis with adenosine receptor agonists
|
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
|
WO2012027695A1
(en)
*
|
2010-08-26 |
2012-03-01 |
Northeastern University |
Methods and compositions for preventing or treating obesity
|
|
ES2556460T3
(es)
*
|
2010-09-29 |
2016-01-18 |
Sk Biopharmaceuticals Co., Ltd. |
Derivados novedosos de metilciclohexano y usos de los mismos
|
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP2646454B1
(en)
|
2010-12-03 |
2015-07-08 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
CN103391939B
(zh)
|
2010-12-03 |
2016-03-09 |
Epizyme股份有限公司 |
作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
|
WO2012145098A1
(en)
*
|
2011-04-21 |
2012-10-26 |
Saint Louis University |
Use of adenosine a3 receptor agonists for treatment of neuropathic pain
|
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
WO2013120078A1
(en)
|
2012-02-11 |
2013-08-15 |
Academia Sinica |
Methods and compositions for treating pain
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
WO2014026198A1
(en)
|
2012-08-10 |
2014-02-13 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
|
EP2892536B1
(en)
|
2012-09-06 |
2019-12-18 |
Epizyme, Inc. |
Method of treating leukemia
|
|
CA2886240A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2014152566A2
(en)
|
2013-03-15 |
2014-09-25 |
Epizyme, Inc. |
Methods of synthesizing substituted purine compounds
|
|
EP3964507A1
(en)
|
2013-10-04 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US20190099404A1
(en)
*
|
2016-03-16 |
2019-04-04 |
Zeno Royalties & Milestones, LLC |
Analgesic compounds
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2018035380A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|